COMPARE · Reviewed July 2, 2026
CPRX vs NBIX
Verdict: Side-by-side breakdown using the Bull Rankings model. CPRX scored 84.4, NBIX scored 87.4 — NBIX ahead by 3.
CPRX
Catalyst Pharmaceuticals, Inc.
84.4
$31.45
Score gap
3
NBIX leads
NBIX
Neurocrine Biosciences, Inc.
87.4
$174.26
The companies
CPRXCatalyst Pharmaceuticals, Inc.
Why now
Biotechnology · market cap $3.9b. 3% off the 52-week high of $32.56. Revenue growing +20%, comfortably above the S&P median. PEG 0.92 — paying under fair value for the growth rate. 3 sell-side analysts publish a mean 1-yr target of $31.67 (implying +1% upside).
Moat
Net margin 37% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 22% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
NBIXNeurocrine Biosciences, Inc.
Why now
Drug Manufacturers - Specialty & Generic · market cap $17.5b. Trading near 52-week high of $174.38 — momentum setup, limited technical margin of safety. Revenue growing +21%, comfortably above the S&P median. PEG 0.48 — paying under fair value for the growth rate. 28 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $195.99 (implying +12% upside).
Moat
Net margin 22% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 20% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 124% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Trading within 0% of the 52-week high — limited technical margin of safety; a momentum reversal would test conviction. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Base grades (each contributes ~14.3% of base composite)
| CPRX | Component | NBIX |
|---|---|---|
| C65 | FCF | C+70 |
| B+85 | Rev | A-90 |
| A95 | D/E | B+85 |
| A-90 | P/E or P/S | B80 |
| B+85 | PEG | A95 |
| Supplemental signals · feed the score, not on the row card | ||
| B+85 | FCF Yield | B80 |
| A-90 | ROE | B+85 |
| 85.2 | Base composite | 83.7 |
Adjustments (signed deltas applied on top of base)
CPRX
compounder synergy (FCF yield ≥5% + ROE ≥15% + D/E <1)+4
GARP sweet spot (PEG <1, positive FCF)+1
forward P/E cheaper (18 → 10)+1
Total+6
NBIX
GARP sweet spot (PEG <1, positive FCF)+1
analyst consensus bullish (86% buy/strong-buy)+2
insider cluster buying (net +28.9%, 64 txns)+2
forward P/E cheaper (27 → 14)+1
Total+6
DCF cross-check (per-share value vs. live price)
| CPRX upside | Horizon | NBIX upside |
|---|---|---|
| -3% | 1Y | -16% |
| -6% | 5Y | +9% |
| -11% | 10Y | +58% |
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.